Traders sold shares of Bristol-Myers Squibb Company (NYSE:BMY) on strength during trading on Thursday. $188.05 million flowed into the stock on the tick-up and $262.40 million flowed out of the stock on the tick-down, for a money net flow of $74.35 million out of the stock. Of all companies tracked, Bristol-Myers Squibb had the 6th highest net out-flow for the day. Bristol-Myers Squibb traded up $2.97 for the day and closed at $62.84

A number of equities research analysts have issued reports on the company. BidaskClub upgraded Bristol-Myers Squibb from a “sell” rating to a “hold” rating in a research note on Saturday, June 10th. Vetr downgraded Bristol-Myers Squibb from a “strong-buy” rating to a “buy” rating and set a $64.20 price target for the company. in a research note on Tuesday, August 22nd. Deutsche Bank AG set a $55.00 price target on Bristol-Myers Squibb and gave the company a “hold” rating in a research note on Monday, July 17th. Credit Suisse Group set a $58.00 price target on Bristol-Myers Squibb and gave the company a “hold” rating in a research note on Wednesday, August 16th. Finally, Jefferies Group LLC restated a “buy” rating and set a $63.00 price target on shares of Bristol-Myers Squibb in a research note on Wednesday, July 12th. One analyst has rated the stock with a sell rating, nine have assigned a hold rating and eleven have assigned a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus price target of $62.42.

The company has a 50-day moving average price of $57.16 and a 200-day moving average price of $55.60. The firm has a market cap of $103.05 billion, a P/E ratio of 22.95 and a beta of 1.18.

Bristol-Myers Squibb (NYSE:BMY) last issued its quarterly earnings data on Thursday, July 27th. The biopharmaceutical company reported $0.74 EPS for the quarter, beating the consensus estimate of $0.73 by $0.01. Bristol-Myers Squibb had a return on equity of 32.33% and a net margin of 22.66%. The company had revenue of $5.14 billion for the quarter, compared to analyst estimates of $5.09 billion. During the same period last year, the company earned $0.69 earnings per share. Bristol-Myers Squibb’s quarterly revenue was up 5.6% compared to the same quarter last year. Equities analysts anticipate that Bristol-Myers Squibb Company will post $2.98 earnings per share for the current year.

In other Bristol-Myers Squibb news, Director Theodore R. Samuels II acquired 6,000 shares of the company’s stock in a transaction on Wednesday, August 2nd. The shares were bought at an average cost of $55.94 per share, with a total value of $335,640.00. Following the completion of the acquisition, the director now owns 18,000 shares in the company, valued at $1,006,920. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.23% of the stock is currently owned by company insiders.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in BMY. American National Bank lifted its position in shares of Bristol-Myers Squibb by 36.0% in the first quarter. American National Bank now owns 1,919 shares of the biopharmaceutical company’s stock valued at $104,000 after acquiring an additional 508 shares in the last quarter. Atria Investments LLC lifted its position in shares of Bristol-Myers Squibb by 15.1% in the first quarter. Atria Investments LLC now owns 40,861 shares of the biopharmaceutical company’s stock valued at $2,222,000 after acquiring an additional 5,349 shares in the last quarter. Community Bank of Raymore lifted its position in shares of Bristol-Myers Squibb by 2.8% in the first quarter. Community Bank of Raymore now owns 6,740 shares of the biopharmaceutical company’s stock valued at $366,000 after acquiring an additional 185 shares in the last quarter. BLB&B Advisors LLC lifted its position in shares of Bristol-Myers Squibb by 3.1% in the first quarter. BLB&B Advisors LLC now owns 89,392 shares of the biopharmaceutical company’s stock valued at $4,861,000 after acquiring an additional 2,660 shares in the last quarter. Finally, First National Bank & Trust Co. of Newtown lifted its position in shares of Bristol-Myers Squibb by 0.3% in the first quarter. First National Bank & Trust Co. of Newtown now owns 42,736 shares of the biopharmaceutical company’s stock valued at $2,324,000 after acquiring an additional 118 shares in the last quarter. Institutional investors and hedge funds own 68.80% of the company’s stock.

WARNING: “Traders Sell Shares of Bristol-Myers Squibb Company (BMY) on Strength (BMY)” was originally posted by Daily Political and is owned by of Daily Political. If you are viewing this article on another domain, it was illegally stolen and republished in violation of international copyright & trademark legislation. The original version of this article can be accessed at https://www.dailypolitical.com/2017/09/07/traders-sell-shares-of-bristol-myers-squibb-company-bmy-on-strength-bmy-3.html.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.